To characterize the molecular mechanisms linking slug activation with tumour progression in vivo, we developed a xenograft model of human HCC progression employing the HepG2-slug cells and parental HepG2 cells as control. The gene discussed is SNAI2; the disease is hepatocellular carcinoma.